Invitrocue Limited announced that the establishment of laboratory facility in Hong Kong. The Hong Kong facility, which will be used for research and development and for commercial purposes, provides Invitrocue with better access to the network of supportive early adopters of its unique Onco-PDOTM technology in the region. This includes primarily oncologists and hospital groups based in Hong Kong and also opportunities in mainland China and Macau. The potential demand from these markets is substantial.